Jupiter Neurosciences Files S-1 for Yorkville Resale Amid Volatile Trading

Ticker: JUNS · Form: S-1 · Filed: Nov 26, 2025 · CIK: 1679628

Sentiment: bearish

Topics: Biotechnology, Emerging Growth Company, Dilution Risk, Standby Equity Purchase Agreement, Nasdaq Capital Market, Pre-revenue Company, High Volatility

Related Tickers: JUNS

TL;DR

**JUNS is burning cash and relying on highly dilutive financing, making it a high-risk, speculative bet for traders.**

AI Summary

Jupiter Neurosciences, Inc. (JUNS) filed an S-1 to register up to 10,000,000 shares of common stock for resale by Yorkville (YA II PN, LTD), a Cayman Islands exempt limited partnership. The company will not receive any proceeds from this specific resale. However, Jupiter Neurosciences may receive up to $6,000,000 from sales of Convertible Notes and up to $14,000,000 from sales of common stock to Yorkville under a Standby Equity Purchase Agreement (SEPA) dated October 24, 2025. The shares being registered include 4,000,000 Conversion Shares, 5,868,091 Advance Shares, and 131,909 shares issued to Yorkville upon SEPA execution. The company has not generated any revenue from product sales to date and expects to incur significant net losses for the foreseeable future, indicating a high-risk profile. JUNS's common stock, listed on Nasdaq, has experienced extreme volatility, trading from a low of $0.51 to a high of $19.51 between December 4, 2024, and November 25, 2025, with a closing price of $1.18 on November 25, 2025. The company recently launched the Nugevia brand of health supplements, which will incur substantial costs and faces intense competition and consumer skepticism.

Why It Matters

This S-1 filing signals Jupiter Neurosciences' continued reliance on dilutive financing mechanisms, specifically through its agreement with Yorkville, to fund operations. For investors, this means potential further dilution of existing shares as up to 10,000,000 shares are registered for resale, and the company may issue more shares to Yorkville for up to $14,000,000. The extreme stock price volatility, ranging from $0.51 to $19.51 in less than a year, highlights significant risk and speculative interest, making it a high-stakes play for traders. The company's lack of revenue and ongoing losses, coupled with the launch of the Nugevia supplement brand into a competitive market, underscores the challenging path to profitability and the speculative nature of its business model, contrasting sharply with established pharmaceutical or consumer health companies.

Risk Assessment

Risk Level: high — The company explicitly states it has 'not generated any revenue from product sales to date' and expects to 'continue to incur significant net losses for the foreseeable future.' Furthermore, its stock price has been extremely volatile, trading from a low of $0.51 to a high of $19.51 between December 4, 2024, and November 25, 2025, indicating significant market uncertainty and speculative trading. The reliance on a Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $14,000,000 in potential common stock sales also points to significant future dilution.

Analyst Insight

Investors should exercise extreme caution and consider the high risk associated with JUNS due to its lack of revenue, ongoing losses, and reliance on dilutive financing. Given the stock's extreme volatility, only investors with a high-risk tolerance and a speculative outlook should consider a position, and even then, with a clear understanding of potential further dilution.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
Significant Net Losses
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is the purpose of Jupiter Neurosciences' S-1 filing?

The S-1 filing by Jupiter Neurosciences, Inc. is to register up to 10,000,000 shares of common stock for resale by YA II PN, LTD (Yorkville). The company itself will not receive any proceeds from this specific resale.

How much money might Jupiter Neurosciences receive from Yorkville?

Jupiter Neurosciences may receive up to $6,000,000 in aggregate gross proceeds from sales of Convertible Notes and up to $14,000,000 in aggregate gross proceeds from sales of common stock to Yorkville under the Standby Equity Purchase Agreement (SEPA).

What is the financial status of Jupiter Neurosciences, Inc.?

Jupiter Neurosciences, Inc. has not generated any revenue from product sales to date and expects to continue to incur significant net losses for the foreseeable future, as stated in the S-1 filing.

What has been the stock price volatility for JUNS?

From December 4, 2024, to November 25, 2025, Jupiter Neurosciences' common stock (JUNS) has traded at a low of $0.51 and a high of $19.51, demonstrating extreme volatility. The closing price on November 25, 2025, was $1.18.

Who is the Selling Stockholder in this S-1 filing for JUNS?

The Selling Stockholder in this S-1 filing for Jupiter Neurosciences, Inc. is YA II PN, LTD, also referred to as Yorkville, a Cayman Islands exempt limited partnership.

What is the Standby Equity Purchase Agreement (SEPA) mentioned in the JUNS S-1?

The SEPA is an agreement dated October 24, 2025, between Jupiter Neurosciences, Inc. and Yorkville, under which Yorkville commits to purchase shares of common stock and convertible notes from the company, providing a financing mechanism.

What are the risks associated with investing in Jupiter Neurosciences?

Investing in Jupiter Neurosciences involves a high degree of risk, including the company's lack of revenue, significant net losses, intense competition for its new Nugevia brand, and extreme volatility in its common stock price, which traded between $0.51 and $19.51 in less than a year.

Is Jupiter Neurosciences considered an 'emerging growth company'?

Yes, Jupiter Neurosciences, Inc. is an 'emerging growth company' under applicable federal securities laws, which subjects it to reduced public company reporting requirements.

What is JOTROL, and what is its significance to Jupiter Neurosciences?

JOTROL is a product candidate being developed by Jupiter Neurosciences. The company's future success is tied to the timing, progress, and results of preclinical studies and planned clinical trials for JOTROL, including demonstrating its safety and efficacy.

What new brand has Jupiter Neurosciences recently launched?

Jupiter Neurosciences recently announced the launch of the Nugevia brand, which provides high-end supplements promoting health and wellness. The company expects to incur substantial costs for this launch and acknowledges intense competition and consumer skepticism.

Risk Factors

Industry Context

Jupiter Neurosciences operates in two distinct but related markets: clinical-stage pharmaceutical development for CNS disorders and the consumer health supplement market. The CNS drug development space is characterized by high R&D costs, long development timelines, and significant regulatory hurdles, with a high failure rate but also the potential for substantial rewards if successful. The health supplement market, where Nugevia is positioned, is highly competitive, crowded with numerous products, and subject to consumer skepticism regarding efficacy and claims.

Regulatory Implications

The company faces significant regulatory scrutiny related to its pharmaceutical development pipeline, particularly for its planned Phase IIa trial in Parkinson's disease. Successful navigation of FDA approval processes, adherence to Good Clinical Practice (GCP) standards, and accurate labeling for its Nugevia product line are critical. Any missteps in regulatory compliance could lead to delays, fines, or product recalls.

What Investors Should Do

  1. Monitor Phase IIa Trial Progress
  2. Assess Nugevia Market Penetration
  3. Evaluate Future Financing Needs and Dilution
  4. Analyze Stock Volatility and Trading Patterns

Key Dates

Glossary

S-1 Filing
A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and management. (This filing provides the basis for the resale of shares by Yorkville and outlines the company's financial situation and future plans.)
Standby Equity Purchase Agreement (SEPA)
An agreement where an investor commits to purchase shares of a company's stock at the company's request, typically over a period of time and at a price determined by market conditions or a formula. (The SEPA with Yorkville provides Jupiter Neurosciences with a flexible source of capital, up to $14,000,000 in common stock sales, but also carries dilution implications.)
JOTROL
Jupiter's proprietary, enhanced resveratrol formulation, which the company believes has improved bioavailability and therapeutic potential for CNS disorders and consumer longevity. (This formulation is central to both the company's prescription drug pipeline and its Nugevia product line, making its efficacy and development critical.)
CNS Disorders
Disorders affecting the central nervous system, which includes the brain and spinal cord. Examples include Parkinson's disease, Alzheimer's disease, and Mild Cognitive Impairment. (Jupiter Neurosciences is developing therapeutic pipelines targeting these disorders, making the success of these programs crucial for the company's future.)
Resveratrol
A natural compound found in foods like grapes and berries, known for its antioxidant properties. The company is focusing on an enhanced formulation (JOTROL) for therapeutic use. (The efficacy and bioavailability of resveratrol, particularly in its enhanced JOTROL form, are key to the company's scientific claims and product development.)

Year-Over-Year Comparison

This S-1 filing represents a significant update as the company is actively pursuing clinical development for CNS disorders and launching a consumer product line, contrasting with potentially earlier-stage or less defined operations in previous filings. Key metrics such as revenue and profitability are not yet meaningful, as the company is pre-revenue and incurring substantial R&D and operational costs. New risks related to clinical trial execution, market acceptance of Nugevia, and ongoing financing needs are prominent in this filing.

Filing Stats: 4,428 words · 18 min read · ~15 pages · Grade level 18.5 · Accepted 2025-11-26 17:28:02

Key Financial Figures

Filing Documents

USE OF PROCEEDS

USE OF PROCEEDS 59 DETERMINATION OF OFFERING PRICE 59 THE STANDBY EQUITY PURCHASE AGREEMENT 59 DIVIDEND POLICY 66 MARKET PRICE FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS 66

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 67 DESCRIPTION OF BUSINESS 78 MANAGEMENT 97

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 105 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 119

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. 121 SELLING STOCKHOLDER 123

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 124 RESTRICTIONS ON RESALE OF SECURITIES 127 PLAN OF DISTRIBUTION 128 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 130 EXPERTS 132 LEGAL MATTERS 132 APPOINTMENT OF NEW AUDITOR 132 DISCLOSURE OF COMMISSION'S POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 132 WHERE YOU CAN FIND ADDITIONAL INFORMATION 133 INDEX TO FINANCIAL STATEMENTS 134 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC to register the securities described in this prospectus for resale by the Selling Stockholder who may, from time to time, sell the securities described in this prospectus. We will not receive any proceeds from the sale of shares of common stock by the Selling Stockholder pursuant to this prospectus. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to these offerings. The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the heading " Where You Can Find More Information ." Neither we nor the Selling Stockholder have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have

Business

Business Overview Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company is advancing a therapeutic pipeline targeting central nervous system ("CNS") disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL , Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a planned Phase IIa clinical study in Parkinson's disease. The Company's Nugevia product line brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company completed preclinical studies at the University of Miami for Parkinson's Disease in 2021. These studies used a validated mouse model to mimic human disease characteristics. The promising results have led the Company to plan a Phase IIa clinical trial for Parkinson's Disease, which is expected to start in the fourth quarter of 2025, with results anticipated 12 months later. The Company also aims to explore other CNS indications, such as Mild Cognitive Impairment ("MCI") and Alzheimer's disease, following the Parkinson's study The Company believes, based on pre-clinical and clinical studies, that high doses of resveratrol are necessary for therapeutic effects. Current resveratrol products cannot reach these levels without causing severe gastrointestinal side effects. Indications are from human studies in Alzheimer's patients (Turner et al 2015) and Friedreich's Ataxia patients (Yu et al 2015) that a concentration at the highest dose (CMax) of resveratrol in blood plasma needs to be 200 ng/ml or higher for therapeutic effect. A Phase 1 study with 500mg of resveratrol as a maximum dose in the JOTROL formulation showed levels of resveratrol exceeding 800 ng/ml

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing